LEAMINGTON, ONT. — Medical cannabis producer Aphria Inc. recently announced the company’s board of directors has approved a $55-million project to build an extraction centre in Leamington, Ont.
The new Extraction Centre of Excellence will be equipped to conduct a range of cannabis extractions, including C02, butane and ethanol, and produce cannabis concentrates, including fractionated distillates, said a media statement.
Construction is expected to begin immediately and the facility is scheduled to release its first concentrates by March 2019.
“The Extraction Centre of Excellence will give Aphria a significant competitive advantage in cannabis concentrates, which are expected to be a significant product category,” said Aphria CEO Vic Neufeld in the statement. “This facility will be the centre of industry-leading R and D and commercial production of next generation cannabis concentrate products.”
The facility will house two class 1/division 1 extraction rooms as well as production, packaging facilities and will have the capacity to process in excess of 200,000 kilograms of cannabis annually.
Combined with other recently announced investments, Aphria will have an increased capacity of 30,000 kilograms, bringing Aphria’s total annualized capacity to 255,000 kilograms.
“We will have ample supply to fulfill our commitments under our supply agreements with provincial retail establishments across Canada and with partners like Shoppers Drug Mart. Our experience and our relentless focus on maintaining an industry-leading low-cost model allows for healthy margins across the supply chain and positions Aphria as an enviable leader in the global cannabis industry,” said Neufeld.
Recent Comments
comments for this post are closed